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was performed in 5, and stents were implanted in 4 cases. In all patients clinical
improvement was observed, with palpable popliteal/foot pulses. In the 30-day
observation, 1 case of subcutaneous hematoma was observed that did not require
surgical treatment. In further observation, the patient underwent revision of the
popliteal artery without bypass surgery. 2 months after the procedure, one patient
underwent balloon angioplasty of the Common Femoral Artery bifurcation without
any intervention on the previously stented segment of the SFA. 4 months after the
procedure, another patient developed recurrent claudication with angiographically
confirmed long SFA occlusion. The recanalization attempt was unsuccessful. In
February 2011, 8 patients underwent control angiography to assess the patency of the
treated SFA segment and, when needed, to qualify them for the next stage procedure.
In 5 patients there was no significant restenosis at the treated segment, in 3 cases such
changes were found and they required a balloon angioplasty without stent implantation.
Conclusion: OCELOT catheter is a novel device and can be safely use for
recanalization of the occluded arteries. It allows, with high efficiency, to avoid
subintimal angioplasty and may reduce the need of stent implantation. Further
observations will help to assess the long term results. It seems reasonable to use Drug
Eluting Balloons in next studies.
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Background: Although endovascular treatment (EVT) became first-line therapy for
peripheral artery disease (PAD), superficial femoral artery (SFA) lesion is still
controversial especially in complex lesion such as chronic total occlusion (CTO). We
investigated midterm patency rate and predictor of restenosis after S.M.A.R.T. self-
expanding nitinol stent implantation for CTO in SFA lesion over large multicenter
registry data.
Methods: From March 2003 to December 2009, serial 940 arteriosclerosis obliterans
patients, 1087 limbs had EVT implanted self-expanding nitinol stent for SFA at 4
hospitals in Japan. Of the cohort, 347 patients 379 limbs implanted S.M.A.R.T. self-
expanding nitinol stent for CTO in SFA and followed for 5 years. We retrospectively
investigated the outcomes, primary and secondary patency rate using Kaplan-Meier
method with logrank test, multivariate analysis used to predict factors associated with
restenosis.
Results: Mean age was 73±9.4 years and female was 32%. Fifty nine percent of
patients had diabetes mellitus, 12% of patients required hemodialysis and 24% was
critical limbs ischemia patients. Average ABI before procedure was 0.56±0.20. In lesion
morphology, occluded length was 195±89 mm, 26% was TASC II AB and 74% was
TASC II CD lesion. Also, reference vessel diameter was 5.4±0.8mm. Mean total stent
length was 198±87 mm, mean stent diameter was 7.0±1.0mm. In the clinical outcomes
13 limbs (3.4%) had major amputation and 9 limbs (2.4%) went to surgery. Forty eight
limbs, 13% detected stent fracture through study period. Five years primary and
secondary patency rate was 68% and 97%, respectively. On multivariate analysis,
female gender (odds ratio, 2.41; p=0.0006), renal insufficiency requiring hemodialysis
(odds ratio, 3.01; p=0.0023), administration of cilostazole (odds ratio, 0.60; p=0.0372),
stent fracture (odds ratio, 2.37; p=0.0131), was the factors associated with restenosis.
Conclusion: Patency rate after S.M.A.R.T. self-expanding nitinol stent implantation
for CTO in SFA lesion up to 5 years seems acceptable. Strong atherosclerotic agents
may associate with restenosis and new stent device tolerate with physical stress,
administration of cilostazole may improve the outcomes.
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Background: Matrix metalloproteinase (MMP-9) not only is involved in both
inflammation and matrix degradation but also is prevalent in the arterial wall
throughout the arterial system. The CD40-CD40L system is a pathway which is
associated with both prothrombotic and proinflammatory effects. The soluble form of
CD40L (sCD40L) is derived mainly from activated platelets and contributes to the
pathophysiology of atherosclerosis. We hypothesized that MMP-9 and sCD40L may
mediate in the development and progression of atherosclerotic lesions. The aim of the
study is to explore the association between serum levels of MMP-9 and sCD40L and
the development and progression of non culprit lesions in patients with coronary artery
disease(CAD).
Methods: We included 80 patients (64 men and 16 women) who underwent two
coronary angiograms with a time interval greater than three months. The culprit lesion
of the first angiogram was clearly identified by a combination of ECG, wall motion
abnormalities, scintigraphic perfusion defects and coronary angiogram. All patients
underwent percutaneous coronary intervention as a treatment for the culprit lesion. In
the second coronary angiography we investigated whether they had a new culprit lesion
clearly differentiated from the culprit lesion of the first angiogram. Samples for plasma
were obtained on admission before the second angiography in all patients. MMP-9 and
sCD40L were assessed by enzyme-linked immunosorbent assay.
Results: In 43 cases was observed progression of the non culprit lesions between the
two angiograms. The mean follow up period was 48 ± 12 months. Mean concentration
of sCD40L was not associated with the progression of the non culprit lesions of the
coronary arteries. However significant association of serum levels of the MMP-9 and
the progression of the non culprit lesions in the coronary arteries was observed. The
subjects with progression of the non culprit lesions had increased mean serum
concentration of MMP-9 in comparison with those that didn’t have any plaque
progression during the follow up period (9.56 ±4.54 ng/L versus 7.43 ±3.23 ng/L,
p=0.007).
Conclusion: The mean concentration of serum levels of MMP-9 in this study was
related to progression of the non culprit lesions in coronary arteries in contrast with
serum levels of sCD40L that seem not to be associated.
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Background: Peri-stent contrast staining (PSS) is an abnormal angiographic finding
at the stent implantation site suggesting contrast staining outside the stent struts, which
does not fulfill the classical definition of coronary artery aneurysm. Imai et al. reported
that PSS found after sirolimus-eluting stent implantation appeared to be associated
with very late stent thrombosis (VLST). However, differences in incidence,
morphological pattern, and time course of PSS between drug-eluting stent (DES) and
bare metal stent (BMS) remain unknown.
Methods: We retrospectively analyzed 6872 lesions with stent implantation from 2001
to 2008. PSS was defined as contrast staining outside the stent contour extending to
20% of the stent diameter. A morphological classification of PSS included monofocal,
multifocal, segmental with irregular, and segmental with smooth. Time course was
classified three types (Regression, no change, progression)
Results: PSS was observed in 131 (1.9%) of the 6872 lesions: BMS, 2.2% (29/1345);
DES, 1.9% (102/5528); p=ns. As shown in the table, however, there were differences
in morphological pattern and time course. Morphologically, monofocal of PSS was
observed more frequent in BMS, and segmental irregular was more frequent in DES.
Regarding the time course, regression type was dominant in BMS. VLST occurred in
6 PSS lesions, of which 4 were segmental irregular and 5 were progression type. No
stent thrombosis occurred in BMS.
Incidence, Morphological Pattern, and Time Course of PSS Between BMS and DES
Conclusion: Although there was no difference in the incidence of PSS between BMS
and DES, morphological pattern and time course were different.
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